hydralazine has been researched along with endothelin-1 in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Filep, JG; Földes-Filep, E; Fournier, A; Skrobik, Y | 1 |
| Filep, JG | 1 |
| Benedetti, G; Benigni, A; Bruzzi, I; Corna, D; Noris, M; Remuzzi, G; Todeschini, M; Zoja, C | 1 |
| Adachi, C; Naruse, K; Naruse, M; Seki, T; Takagi, S; Takano, K; Tanabe, A; Yoshimoto, T | 1 |
| Jenkins, DG; McEniery, CM; Webb, DJ; Wilkinson, IB | 1 |
| Harris, AL; Knowles, HJ; Mole, DR; Tian, YM | 1 |
| Abe, Y; Fan, Y; Kimura, S; Kobori, H; Nishiyama, A; Rahman, M; Seth, DM; Shokoji, T; Yao, L; Zhang, GX | 1 |
| Gabriëls, G; Grisk, O; Lother, U; Rettig, R | 1 |
| Callera, GE; Carvalho, MH; Fortes, ZB; Montezano, AC; Mota, AL; Nigro, D; Tostes, RC; Zorn, TM | 1 |
| Chang, NC; Chen, CC; Lee, TM; Lin, MS | 1 |
| Agharazii, M; Bélanger, S; Larivière, R; Lebel, M; Lemieux, P; Therrien, F | 1 |
1 trial(s) available for hydralazine and endothelin-1
| Article | Year |
|---|---|
Endogenous endothelin-1 limits exercise-induced vasodilation in hypertensive humans.
Topics: Adult; Antihypertensive Agents; Cross-Over Studies; Endothelin Receptor Antagonists; Endothelin-1; Forearm; Hand Strength; Humans; Hydralazine; Hypertension; Infusions, Intra-Arterial; Male; Middle Aged; Peptides, Cyclic; Regional Blood Flow; Single-Blind Method; Time Factors; Vasodilation | 2002 |
10 other study(ies) available for hydralazine and endothelin-1
| Article | Year |
|---|---|
Effects of calcium antagonists on endothelin-1-induced myocardial ischaemia and oedema in the rat.
Topics: Albumins; Animals; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, Drug; Edema; Electrocardiography; Endothelin-1; Endothelins; Heart Rate; Hydralazine; Male; Myocardial Ischemia; Nifedipine; Peptide Fragments; Rats; Rats, Wistar; Receptors, Endothelin; Vasodilator Agents; Verapamil | 1996 |
Endogenous endothelin modulates blood pressure, plasma volume, and albumin escape after systemic nitric oxide blockade.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Azepines; Blood Pressure; Bosentan; Data Interpretation, Statistical; Endothelin Receptor Antagonists; Endothelin-1; Hydralazine; Indoles; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Plasma Volume; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Serum Albumin; Sulfonamides; Time Factors; Vasodilator Agents | 1997 |
Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Creatinine; Disease Progression; Eating; Endothelin-1; Hydralazine; Hydrochlorothiazide; Kidney; Lisinopril; Male; Molsidomine; Nephrectomy; Nitric Oxide; Nitric Oxide Donors; Nitrous Oxide; Rats; Rats, Sprague-Dawley; Reserpine | 1999 |
Hydralazine decreases blood pressure and endothelin-1 mRNA expression in tissues but not cardiac weight in SHR-SP/Izm rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Cardiomegaly; Endothelin-1; Hydralazine; Male; Organ Size; Rats; Rats, Inbred SHR; RNA, Messenger | 2000 |
Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases.
Topics: Adrenomedullin; Angiogenesis Inducing Agents; Animals; Breast Neoplasms; Carcinoma; Carcinoma, Renal Cell; Cell Hypoxia; Cell Line, Tumor; Cells, Cultured; DNA-Binding Proteins; Dose-Response Relationship, Drug; Endothelial Cells; Endothelin-1; Enzyme Inhibitors; Gene Expression Regulation; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Hydralazine; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Implants, Experimental; Kidney Neoplasms; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Myocytes, Smooth Muscle; Neovascularization, Physiologic; Nuclear Proteins; Peptides; Procollagen-Proline Dioxygenase; Transcription Factors; Vascular Endothelial Growth Factor A; Vasodilator Agents | 2004 |
Olmesartan improves endothelin-induced hypertension and oxidative stress in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Endothelin-1; Hydralazine; Hypertension; Imidazoles; Male; Olmesartan Medoxomil; Oxidative Stress; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Superoxides; Tetrazoles; Thiobarbituric Acid Reactive Substances | 2004 |
Influence of neonatal sympathectomy on proximal renal resistance artery function in spontaneously hypertensive rats.
Topics: Animals; Animals, Newborn; Antihypertensive Agents; Blood Pressure; Calcium; Calcium Channels, L-Type; Catecholamines; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Endothelin-1; Endothelium, Vascular; Hydralazine; Kidney Tubules, Proximal; Muscle Relaxation; Muscle, Smooth, Vascular; Myography; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Rats; Rats, Inbred SHR; Renal Artery; Sympathectomy, Chemical; Vascular Resistance; Vasodilation | 2005 |
Endothelin-1 contributes to the sexual differences in renal damage in DOCA-salt rats.
Topics: Animals; Dansyl Compounds; Desoxycorticosterone; Disease Models, Animal; Endothelin-1; Estrogens; Female; Hydralazine; Hypertension; Kidney; Kidney Diseases; Male; Ovariectomy; Progesterone; Rats; Rats, Wistar; Receptor, Endothelin A; RNA, Messenger; Sex Characteristics; Sodium Chloride | 2005 |
Effect of endothelin receptor antagonists on ventricular susceptibility in postinfarcted rats.
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atrasentan; Blotting, Western; Bosentan; Cardiac Pacing, Artificial; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; GAP-43 Protein; Hemodynamics; Hydralazine; Immunohistochemistry; Male; Methoxyhydroxyphenylglycol; Myocardial Infarction; Myocardium; Nerve Growth Factor; Neurofilament Proteins; Norepinephrine; Polymerase Chain Reaction; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; RNA, Messenger; Sulfonamides; Sympathetic Nervous System; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation | 2008 |
Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Endothelin-1; Hydralazine; Hypertension, Malignant; Losartan; Male; Necrosis; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renal Insufficiency | 2009 |